NGF and early-onset autosomal dominant Alzheimer disease: The fact that the NGF mutation R100W appears, from a clinical point of view, toseparate the effects of NGF on CNS development from those involved in the activationof adult peripheral pain pathways, could provide a basis for designing“painless” NGF variant molecules, tailored for therapeutic applicationsin Alzheimer's disease [60], circumventing the most serious hurdle that have limitedsuch applications.